Lunai Bioworks, an AI-driven precision medicine company, filed a Second Amended Complaint in U.S. District Court accusing six registered broker-dealers and two principals of securities fraud and market manipulation. This legal action expands the list of defendants and aims to address alleged misconduct affecting the company. The case is ongoing, with potential implications for the involved parties and investors. Lunai cautions that outcomes are uncertain and subject to legal risks.
Toast's Chief Revenue Officer has sold nearly 14,000 shares as the company's stock price has surged over 50% in the past three months. This insider sale comes at a time when investor confidence appears strong, reflecting positive market sentiment tow...
Kohl's reported a strong adjusted EPS of $1.28 for Q2, more than doubling analyst expectations due to a 43% gross margin boosted by one-time tariff refunds. However, the retailer's total revenue and comparable sales fell by 0.9%, marking the 18th con...
Royal Bank of Canada reported strong Q3 2026 results, surpassing earnings per share estimates with $3.07 versus $2.89 expected, marking a 6.23% positive surprise and continuing a streak of four quarters beating expectations. Revenue also exceeded for...
Evercore ISI increased its price target for Williams-Sonoma to $245 following a strong Q2 performance, with revenue up 6.7% to $1.96 billion and comparable sales rising 6.2%, beating expectations. The gross margin improved to 51.6%, partly due to one...
RBC Capital reaffirmed its 'Sector Perform' (hold) rating on FactSet, increasing the price target from $240 to $304 as of August 27, 2026. Despite this optimistic price target adjustment, the broader market remains cautious, with an average 'Reduce' ...
